MRS 2578 is a potent and selective P2Y6 receptor antagonist (IC₅₀=37nM). MRS 2578 can regulate purinergic signaling by inhibiting UDP-induced inositol phospholipid accumulation and blocking the protective effect of UDP against TNFα-induced apoptosis. MRS 2578 reduces inflammatory responses by inhibiting NF-κB activity. MRS 2578 can be used in research related to vascular function, inflammatory diseases, and neuroprotection[1-4].
In vitro, MRS 2578 (5-10μM) was used to treat colorectal cancer cell lines (SW480 and HCT116) for 24-72 hours. MRS 2578 significantly inhibited cell viability and increased cell sensitivity to etoposide[5]. MRS 2578 (37nM) was used to pretreat HeLa cells 60 minutes before the addition of tested nucleotides (100μM). MRS 2578 blocked UDP-, UTP-, and TMPS-mediated migratory responses of HeLa cells[6].
In vivo, MRS 2578 (3mg/kg) was administered intraperitoneally once daily for 3 days to ICR mice subjected to transient middle cerebral artery occlusion (tMCAO). MRS 2578 significantly enlarged brain atrophy and edema volume and aggravated neurological function deficits[7]. MRS 2578 (2mg/kg) was administered as a single intratumoral injection to C57BL/6 mice bearing EL-4 lymphoma. MRS 2578 significantly reduced tumor growth, decreased the migratory potential of tumor cells, and improved the behavioral responses of the mice[8].
References:
[1] Mamedova LK, Joshi BV, Gao ZG, et al. Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochem Pharmacol. 2004 May 1;67(9):1763-70.
[2] Nishida M, Sato Y, Uemura A, et al. P2Y6 receptor-Galpha12/13 signalling in cardiomyocytes triggers pressure overload-induced cardiac fibrosis. EMBO J. 2008 Dec 3;27(23):3104-15.
[3] Riegel AK, Faigle M, Zug S, et al. Selective induction of endothelial P2Y6 nucleotide receptor promotes vascular inflammation. Blood. 2011 Feb 24;117(8):2548-55.
[4] Vieira RP, Müller T, Grimm M, et al. Purinergic receptor type 6 contributes to airway inflammation and remodeling in experimental allergic airway inflammation. Am J Respir Crit Care Med. 2011 Jul 15;184(2):215-23.
[5] Li X, Wu Z, An X, et al. Blockade of the LRP16-PKR-NF-κB signaling axis sensitizes colorectal carcinoma cells to DNA-damaging cytotoxic therapy. Elife. 2017 Aug 18;6:e27301.
[6] Gendaszewska-Darmach E, Szustak M. Thymidine 5'-O-monophosphorothioate induces HeLa cell migration by activation of the P2Y6 receptor. Purinergic Signal. 2016 Jun;12(2):199-209.
[7] Wen RX, Shen H, Huang SX, et al. P2Y6 receptor inhibition aggravates ischemic brain injury by reducing microglial phagocytosis. CNS Neurosci Ther. 2020 Apr;26(4):416-429.
[8] Ghimeray K, Sharma S, Rahman MM, et al. P2Y6 receptor inhibition arrests tumor cell progression in a mouse lymphoma model. Nucleosides Nucleotides Nucleic Acids. 2025 Nov 7:1-19.
MRS 2578是一种有效的、选择性的P2Y6受体拮抗剂（IC50=37nM）。MRS 2578可通过抑制UDP诱导的肌醇磷脂积累和阻断UDP对TNFα诱导的细胞凋亡的保护作用来调控嘌呤能信号。MRS 2578通过抑制NF-κB活性以减少炎症反应。MRS 2578可用于血管功能、炎症性疾病和神经保护的相关研究[1-4]。
在体外，MRS 2578（5-10μM）处理结直肠癌细胞系（SW480和HCT116）24-72小时，MRS 2578显著抑制细胞活力，并增加细胞对依托泊苷的敏感性[5]。MRS 2578（37nM）在添加测试核苷酸（100μM）前60分钟预处理HeLa细胞。MRS 2578阻断了UDP、UTP和TMPS介导的HeLa细胞迁移反应[6]。
在体内，MRS 2578（3mg/kg）每天一次腹腔注射于经历短暂性大脑中动脉闭塞（tMCAO）的ICR小鼠，持续3天。MRS 2578显著增大了脑萎缩和水肿体积，并加重了神经功能缺损[7]。MRS 2578（2mg/kg）单次瘤内注射于携带EL-4淋巴瘤的C57BL/6小鼠。MRS 2578显著减少了肿瘤生长，降低了肿瘤细胞的迁移潜力，并改善了小鼠的行为反应[8]。